Holen Sie sich die Stockscreener-App
1.64
2.96%
-0.05
Handel nachbörslich:
1.65
0.01
+0.61%
Schlusskurs vom Vortag:
$1.69
Offen:
$1.725
24-Stunden-Volumen:
911.50K
Relative Volume:
0.78
Marktkapitalisierung:
$103.47M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-1.038
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
+7.89%
1M Leistung:
-4.09%
6M Leistung:
-35.43%
1J Leistung:
-53.01%
1-Tages-Spanne:
$1.64
$1.79
1-Wochen-Bereich:
$1.44
$1.79
52-Wochen-Spanne:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Vergleichen Sie MGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.64 | 96.07M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
Technical Models Detect Momentum Build in MacroGenics Inc.July 2025 Reactions & Stock Portfolio Risk Control - classian.co.kr
Elliott Wave Theory Predicts Pullback in MacroGenics Inc.July 2025 Outlook & Consistent Growth Equity Picks - classian.co.kr
MacroGenics Inc. Breakout Confirmed by Volume MetricsPortfolio Return Report & AI Driven Stock Movement Reports - thegnnews.com
DC InnoMacroGenics strikes potential $1.7B deal with Gilead | Quantum Computing is expanding - The Business Journals
Is it too late to sell MacroGenics Inc.Earnings Growth Summary & Weekly Chart Analysis and Guides - Newser
What to expect from MacroGenics Inc. in the next 30 daysEarnings Risk Report & Consistent Profit Focused Trading Strategies - Newser
Can MacroGenics Inc. grow without dilution2025 Growth vs Value & Verified Short-Term Trading Plans - thegnnews.com
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
What candlestick patterns are forming on MacroGenics Inc.Gap Up & Risk Controlled Stock Alerts - Newser
What the charts say about MacroGenics Inc. todayWeekly Trade Analysis & Reliable Entry Point Alerts - Newser
Is MacroGenics Inc. stock ready for a breakoutJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser
Is now a turning point for MacroGenics Inc.Quarterly Portfolio Summary & Low Volatility Stock Recommendations - Newser
Leerink Partners Has Lowered Expectations for MacroGenics (NASDAQ:MGNX) Stock Price - Defense World
Will MacroGenics Inc. see short term momentumMarket Activity Summary & Consistent Profit Focused Trading Strategies - Newser
Why MacroGenics Inc. stock attracts strong analyst attention2025 Stock Rankings & Real-Time Chart Pattern Alerts - Newser
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates - MSN
MacroGenics price target lowered to $5 from $8 at Leerink - MSN
Rockville’s MacroGenics Appoints New President/CEO For First Time in 24 Years - The MoCo Show -
MacroGenics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
How MacroGenics Inc. stock performs during market volatilityEarnings Beat & Community Supported Trade Ideas - Newser
Macrogenics, Inc. shares fall 1.27% after-hours following Johnson & Johnson's presentation at BofA Securities 2025. - AInvest
MacroGenics appoints Eric Risser as CEO as Scott Koenig exits - The Business Journals
Macrogenics: Leerink Partners lowers PT to $5, maintains Outperform rating. - AInvest
MacroGenics' CEO Transition and Lorigerlimab Trial Uncertainty Warrant Hold Rating Amid Partnership Exploration - AInvest
MacroGenics Price Target Lowered to $5 at Leerink - AInvest
MacroGenics Inc. Reports Q2 2025 Financial Results - MSN
Macrogenics 2025 Q2 Earnings Narrowed Losses and Strong Revenue Growth - AInvest
MacroGenics stock maintains Market Perform rating at Citizens JMP By Investing.com - Investing.com Canada
MacroGenics: Q2 Earnings Snapshot - Greenwich Time
MacroGenics (MGNX): Strategic Transition, Pipeline Progress, and Liquidity Outlook for Biotech Investors - AInvest
Macrogenics Inc (MGNX) Q2 2025 Earnings: EPS of -$0.57 Beats Est - GuruFocus
MacroGenics appoints new CEO - MSN
MacroGenics Slows Its Losses And Adds $70 Million To The Bank - Finimize
MacroGenics reports Q2 EPS (57c), consensus (38c) - TipRanks
MacroGenics Revenue Doubles in Q2 - The Globe and Mail
MacroGenics Appoints Eric Risser as New CEO - The Globe and Mail
MacroGenics Inc earnings missed by $0.11, revenue fell short of estimates - Investing.com Nigeria
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities - GlobeNewswire
MacroGenics Reports Q2 2025 Financials, Updates Key Strategic Priorities - AInvest
MacroGenics Extends Cash Runway to 2027 with $70M Royalty Deal as New CEO Unveils Strategic Roadmap - Stock Titan
MacroGenics Inc. Approaches Psychological Resistance LevelJuly 2025 Volume & Advanced Swing Trade Entry Alerts - classian.co.kr
MacroGenics’ MGC026 Study: A New Hope for Advanced Solid Tumors? - TipRanks
MacroGenics promotes Eric Risser to president and CEO - The Pharma Letter
MacroGenics' Leadership Transition: A Strategic Inflection Point for Capital Efficiency and Growth - AInvest
Short Term Charts Align With Long Term Uptrend in MacroGenics Inc.July 2025 Intraday Action & Weekly Market Pulse Updates - beatles.ru
MacroGenics Appoints Eric Risser As CEO - MarketScreener
MacroGenics names Eric Risser as new CEO, succeeding Scott Koenig By Investing.com - Investing.com Nigeria
MacroGenics appoints Eric Risser as new CEO, succeeding Scott Koenig By Investing.com - Investing.com Nigeria
MacroGenics names Eric Risser as new CEO, succeeding Scott Koenig - Investing.com India
MacroGenics Appoints Eric Risser as President and Chief Executive Officer | MGNX Stock News - GuruFocus
MacroGenics appoints Eric Risser as new CEO, succeeding Scott Koenig - Investing.com
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Macrogenics Inc-Aktie (MGNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
| Bonvini Ezio | Sr VP, Research & CSO |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
124,414 |
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
1.38%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):